journal article·2025-12Open access

SLC7A11-independent disulfidptosis induced by a two-pronged delivery strategy for bladder cancer chemotherapy and cisplatin-resistance reverse

Bin Zheng, Facai Zhang, Heng Wang, Wenyan Zuo, Dingyi Liu, Zhihan Wu, Zhenghong Liu, Haichang Li, Yang Liu, Yixuan Mou, Xiaowen Qin, Dahong Zhang, Pu Zhang, Qi Zhang

Abstract

The intracellular overload of disulfide is induced by the imbalance between cystine (Cys) uptake and intracellular Cys reduction, leading to disulfidptosis. Solute carrier family 7 member 11 (SLC7A11) is a Cys transporter at the cell surface, and its high level of expression, together with glucose deprivation, is a requisite determining the disulfidptosis induction. Recent studies have exploited glucose deprivation by multifunctional nanomaterials as mainstream to evoke disulfidptosis, unfortunately with a strong bias to SLC7A11 highly expressed tumors. Despite many efforts to modulate SLC7A11 expression, the uncertainty brought by complex biological mechanisms under different exposure inspired us to find a more solid approach to raise Cys-uptake efficiency. In this study, we developed a two-pronged approach to deplete glucose and enrich intracellular Cys by co-biomineralizing Cys, glucose oxidase (Gox), and manganese as one entity, further cloaked with tumor cell membrane (M@Cys-Gox-Mn) to enhance tumor-selective uptake. M@Cys-Gox-Mn nanoparticles (NPs) displayed no SLC7A11-dependence for Cys transport and their synergistic action of the dual enzymes enables self-amplifying glucose depletion, thus exacerbating the disulfide stress. The use of M@Cys-Gox-Mn NPs as monotherapy greatly combat orthotopic bladder tumors, and the combination with cisplatin overcome the chemoresistance. Both therapies achieved complete tumor inhibition with favorable biosafety.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Sulfur Compounds in Biology · Cancer, Hypoxia, and Metabolism · Redox biology and oxidative stress

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (22)

Show source-provided references
1. Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis10.1038/s41556-023-01091-2 ↗
2. Disulfidptosis: disulfide stress-induced cell death10.1016/j.tcb.2023.07.009 ↗
3. Disulfidptosis: a new target for metabolic cancer therapy10.1186/s13046-023-02675-4 ↗
4. Programable prodrug nanomodulator targets tumor redox homeostasis imbalance to amplify disulfidptosis and immunogenic pyroptosis for breast tumor immunotherapy10.1002/adhm.202500272 ↗
5. Bioactive nanoliposomes for enhanced sonodynamic-triggered disulfidptosis-like cancer cell death via lipid peroxidation10.2147/IJN.S464178 ↗
6. A novel FTO-Targeting nanodrug induces disulfidptosis and ameliorates the suppressive tumor immune environment to treat uveal melanoma
7. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy, protein
8. Synchronously evoking disulfidptosis and ferroptosis via systematical glucose deprivation targeting SLC7A11/GSH/GPX4 antioxidant axis10.1021/acsnano.5c00730 ↗
9. A multiple-response Cascade nanoreactor for starvation and deep catalysis chemodynamic assisted Near-Infrared-II mild photothermal therapy10.1021/cbmi.2c00003 ↗
10. Biomineralization-inspired synthesis of amorphous manganese phosphates for GLUT5-targeted drug-free catalytic therapy of osteosarcoma10.1039/D1NR06220D ↗
11. Zeta potential and colloidal stability predictions for inorganic nanoparticle dispersions: effects of experimental conditions and electrokinetic models on the interpretation of results10.1021/acs.langmuir.1c02056 ↗
12. Disrupting intracellular homeostasis by copper-based nanoinducer with multiple enzyme-mimicking activities to induce disulfidptosis-enhanced pyroptosis for tumor immunotherapy10.1002/adma.202410957 ↗
13. ZIF-8 nanoparticles evoke pyroptosis for high-efficiency cancer immunotherapy10.1002/anie.202215307 ↗
14. Biomineralized two-enzyme nanoparticles regulate tumor glycometabolism inducing tumor cell pyroptosis and robust antitumor immunotherapy10.1002/adma.202206851 ↗
15. Control of gasdermin D oligomerization and pyroptosis by the Ragulator-Rag-mTORC1 pathway10.1016/j.cell.2021.06.028 ↗
16. SLC7A11 expression level dictates differential responses to oxidative stress in cancer cells10.1038/s41467-023-39401-9 ↗
17. Endocytosis by random initiation and stabilization of clathrin-coated pits10.1016/j.cell.2004.08.017 ↗
18. Caveosomes and endocytosis of lipid rafts10.1242/jcs.00840 ↗
19. Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells10.1038/s41598-021-89684-5 ↗
20. Cancer cell membrane-coated nanoparticles: a promising anti-tumor bionic platform10.1039/D4RA01026D ↗
21. Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms
22. Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A1110.1158/1078-0432.CCR-13-2805 ↗